Dailiport Hart forðahylki 3 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dailiport hart forðahylki 3 mg

sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 3 mg

Vivelle dot Forðaplástur 100 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 100 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 100 míkróg

Vivelle dot Forðaplástur 25 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 25 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 25 míkróg

Vivelle dot Forðaplástur 37,5 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 37,5 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 37,5 míkróg

Vivelle dot Forðaplástur 50 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 50 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 50 míkróg

Vivelle dot Forðaplástur 75 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 75 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 75 míkróg

Zofran Filmuhúðuð tafla 4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 4 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Zofran Filmuhúðuð tafla 8 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 8 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Zofran Mixtúra, lausn 0,8 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran mixtúra, lausn 0,8 mg/ml

sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml

Tyruko Evrópusambandið - íslenska - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalízúmab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.